Evidence map›Paper›PMID 38306009›Full record

Observational studyEndocrine2024

Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: a single center retrospective observational study.

Yanting Shen, Yu Luo, Minghao Li, Rongkui Luo, Lingli Chen, Xin Gao, Jingjing Jiang, Yujun Liu, Zhiqiang Lu, Jing Zhang

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yanting Shen *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu Luo *Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Minghao Li *Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lingli ChenDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xin GaoDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingjing JiangDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Yujun LiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.yujun@zs-hospital.sh.cn.
Zhiqiang LuDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. lu.zhiqiang@zs-hospital.sh.cn.
Jing ZhangDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. zhang.jing9@zs-hospital.sh.cn.ORCID 0000-0003-1958-8169
Sun Yat-sen University · CNFudan University · CNCentral South University · CN

Funding

National Natural Science Foundation of China 82200894Youth Foundation of Zhongshan Hospital Fudan University LCBSHZX013
6 · The paper itself

Abstract

purposeAdrenal and extra-adrenal paragangliomas (PGLs) are a group of neuroendocrine tumors (NETs) with strong heterogeneity, which often express somatostatin receptor subtype 2 A (SSTR2A). However, the association between SSTR2A expression and genetic status of PGLs remains unclear. The purpose of the study was to identify whether various pathogenic variants (PVs) had an impact on SSTR2A expression in PGLs.

methodsThis retrospective study included 184 patients with pathologically confirmed PGLs. The immunohistochemical expression of SSTR2A were studied in 184 tumors and PVs were tested in 159 tumor samples. Clinical and genetic data were compared in SSTR2A positive and negative PGLs.

resultsSSTR2A was positive in 63.6% (117/184) of all tumors. PGLs with negative SSTR2A were more likely to be extra-adrenal (37.0% vs 18.0%; P = 0.005) and exhibited a considerably greater proportion of PVs (75.4% vs. 49.0%; P = 0.001) than those with positive SSTR2A. Compared to those without PVs, a higher proportion of PGLs with PVs in cluster 1B (P = 0.004) and cluster 2 (P = 0.004) genes, especially VHL (P = 0.009), FGFR1 (P = 0.010) and HRAS (P = 0.007), were SSTR2A negative. SSTR2A was positive in all tumors (4/4) with SDHx PVs and in 87.5% (7/8) of metastatic PGLs.

conclusionsSSTR2A negativity was correlated with extra-adrenal tumor location and PVs in cluster 1B and cluster 2 genes such as VHL, FGFR1 and HRAS. Immunohistochemistry of SSTR2A should be taken into consideration in the personalized management of PGLs.

Indexed as

ParagangliomaReceptors, SomatostatinAdolescentAdrenal Gland NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultReceptors, Somatostatinsomatostatin receptor 2somatostatin receptor sst2ASSTR2 protein, humanGeneticsImmunohistochemistryParagangliomasPheochromocytomasSomatostatin receptor sst2A

Identifiers

PMID38306009
OpenAlexW4391474050

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.